Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 56,376 | 40,005 | 55,706 | 48,714 | 126,365 |
| Cost of Goods | 17,284 | 20,189 | -2,657 | 38,281 | 18,600 |
| Gross Profit | 39,092 | 19,816 | 58,363 | 10,433 | 107,765 |
| Operating Expenses | 48,372 | 45,602 | 63,662 | 61,119 | 74,290 |
| Operating Income | -8,996 | -25,597 | -5,956 | -50,405 | 34,075 |
| Interest Expense | 1,642 | 1,561 | 1,636 | 3,952 | 5,037 |
| Other Income | -534 | 282 | 434 | 261 | 411 |
| Pre-tax Income | -11,172 | -26,876 | -7,158 | -54,096 | 29,449 |
| Net Income Continuous | -11,172 | -26,876 | -7,158 | -54,096 | 29,449 |
| Net Income | $-11,172 | $-26,876 | $-7,158 | $-54,096 | $29,449 |
| EPS Basic Total Ops | -0.06 | -0.15 | -0.04 | -0.29 | 0.16 |
| EPS Basic Continuous Ops | -0.06 | -0.15 | -0.03 | -0.29 | 0.16 |
| EPS Diluted Total Ops | -0.06 | -0.15 | -0.03 | -0.29 | 0.15 |
| EPS Diluted Continuous Ops | -0.06 | -0.15 | -0.03 | -0.29 | 0.15 |
| EPS Diluted Before Non-Recurring Items | -0.06 | -0.14 | -0.04 | N/A | N/A |
| EBITDA(a) | $411 | $-16,188 | $3,463 | $-40,981 | $43,501 |